[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Nurix Therapeutics Inc (NRIX)

Nurix Therapeutics Inc (NRIX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,685,878
  • Shares Outstanding, K 103,782
  • Annual Sales, $ 83,980 K
  • Annual Income, $ -264,460 K
  • EBIT $ -361 M
  • EBITDA $ -353 M
  • 60-Month Beta 1.79
  • Price/Sales 31.55
  • Price/Cash Flow N/A
  • Price/Book 6.56

Options Overview Details

View History
  • Implied Volatility 72.33% (-4.78%)
  • Historical Volatility 36.80%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 325.58% on 09/18/25
  • IV Low 72.33% on 08/11/26
  • Expected Move (DTE 9) 0.00 (0.00%)
  • Put/Call Vol Ratio 3.35
  • Today's Volume 344
  • Volume Avg (30-Day) 113
  • Put/Call OI Ratio 0.53
  • Today's Open Interest 2,623
  • Open Int (30-Day) 2,721
  • Expected Range 25.96 to 25.96

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 08/31/26
See More
  • Average Estimate $-0.56
  • Number of Estimates 5
  • High Estimate $-0.27
  • Low Estimate $-0.75
  • Prior Year $-1.03
  • Growth Rate Est. (year over year) +45.63%

Price Performance

See More
Period Period Low Period High Performance
1-Month
21.23 +22.28%
on 07/13/26
26.36 -1.52%
on 08/11/26
+2.90 (+12.58%)
since 07/10/26
3-Month
14.24 +82.30%
on 06/05/26
26.36 -1.52%
on 08/11/26
+9.68 (+59.46%)
since 05/11/26
52-Week
8.19 +216.78%
on 09/23/25
26.36 -1.52%
on 08/11/26
+16.31 (+169.02%)
since 08/11/25

Most Recent Stories

More News
Nurix Announces $10 Million Milestone Payment Associated with Initiation of a Phase 1 Clinical Trial of a STAT6 Degrader

Oral STAT6 degrader advances into clinical development for type 2 inflammatory diseases Nurix has earned approximately $139 million to date under its collaboration with Sanofi and remains eligible...

NRIX : 25.96 (+0.31%)
Nurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

BRISBANE, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX) today announced that the first patient has been enrolled in the global Phase 3 DAYBreak CLL-306 study (NCT07516093)...

NRIX : 25.96 (+0.31%)
Nurix Therapeutics Announces HSR Clearance of Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology

BRISBANE, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...

NRIX : 25.96 (+0.31%)
Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Entered into global collaboration with Roche for bexobrutideg, with potential total payments of up to $2.3 billion, including $700 million upfront payment Co-development, co-commercialization collaboration...

NRIX : 25.96 (+0.31%)
Nurix Therapeutics Reports This Week With Its Cash Runway Now a More Urgent Question

Barchart Research What to Expect from NRIX Earnings NRIX Generated July 7, 2026 Current Price $24.40 EPS Estimate $$-0.73 Consensus Rating Strong Buy Average Move 6.53% Nurix Therapeutics Reports This...

NRIX : 25.96 (+0.31%)
Nurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory CLL/SLL and Promising Activity in Earlier Lines of Therapy

High objective response rate of 92.9% in second line patients who have progressed on a BTK inhibitor and have not received BCL2 inhibitor treatment Updated Phase 1a data further supports a median...

NRIX : 25.96 (+0.31%)
Broader Market Settles Higher as Chipmakers Rally

The S&P 500 Index ($SPX ) (SPY ) on Monday closed up +0.30%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed down -0.16%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +1.58%. June E-mini...

MSTR : 96.09 (-1.27%)
MPC : 336.42 (+5.03%)
AAPL : 304.91 (-1.09%)
SNDK : 1,271.05 (+2.68%)
GLXY : 20.13 (+3.12%)
SLB : 53.68 (+0.90%)
COIN : 148.58 (-0.07%)
CIEN : 387.53 (-0.04%)
FANG : 201.71 (+1.38%)
STX : 820.52 (+2.44%)
WDC : 437.93 (-0.09%)
AMD : 474.32 (+1.01%)
Stocks Rally as Buyers Return After AI-Led Selloff

The S&P 500 Index ($SPX ) (SPY ) today is up +1.01%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.46%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +2.39%. June E-mini S&P futures (ESM26...

MSTR : 96.09 (-1.27%)
MPC : 336.42 (+5.03%)
SNDK : 1,271.05 (+2.68%)
ADI : 385.30 (+0.36%)
GLXY : 20.13 (+3.12%)
SLB : 53.68 (+0.90%)
COIN : 148.58 (-0.07%)
CIEN : 387.53 (-0.04%)
FANG : 201.71 (+1.38%)
STX : 820.52 (+2.44%)
WDC : 437.93 (-0.09%)
AMD : 474.32 (+1.01%)
Stocks Push Higher as Chipmakers and AI Companies Rebound

The S&P 500 Index ($SPX ) (SPY ) today is up +0.65%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.21%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.59%. June E-mini S&P futures (ESM26...

MSTR : 96.09 (-1.27%)
AMAT : 525.61 (+0.67%)
AVGO : 416.08 (-1.50%)
SNDK : 1,271.05 (+2.68%)
ADI : 385.30 (+0.36%)
GLXY : 20.13 (+3.12%)
WIX : 66.71 (+6.86%)
$IUXX : 29,525.48 (unch)
COIN : 148.58 (-0.07%)
ZNU26 : 108-160 (+0.01%)
CIEN : 387.53 (-0.04%)
ESU26 : 7,755.00 (+0.10%)
Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology

Strategic collaboration combines Nurix’s leadership in targeted protein degradation with Roche’s portfolio of B-cell targeted therapies and global clinical and commercialization footprint Robust...

NRIX : 25.96 (+0.31%)
RHHBY : 56.6200 (-1.41%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength is above 70%. The market is in overbought territory. Watch for a potential trend reversal.

See More Share

Business Summary

Nurix Therapeutics Inc.is a biopharmaceutical company. It focuses on the discovery, development and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company's product candidates include NX-2127 and NX-1607 which are in clinical stage. Nurix Therapeutics...

See More

Key Turning Points

3rd Resistance Point 27.29
2nd Resistance Point 26.83
1st Resistance Point 26.39
Last Price 25.96
1st Support Level 25.49
2nd Support Level 25.03
3rd Support Level 24.59

See More

52-Week High 26.36
Last Price 25.96
Fibonacci 61.8% 19.42
Fibonacci 50% 17.28
Fibonacci 38.2% 15.13
52-Week Low 8.19

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.